These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 37917181

  • 41. Understanding improved dissolution of indomethacin through the use of cohesive poorly water-soluble aluminium hydroxide: effects of concentration and particle size distribution.
    Tay T, Allahham A, Morton DA, Stewart PJ.
    J Pharm Sci; 2011 Oct; 100(10):4269-80. PubMed ID: 21560127
    [Abstract] [Full Text] [Related]

  • 42. Molecular-Level Examination of Amorphous Solid Dispersion Dissolution.
    Faiz Afzal MA, Lehmkemper K, Sobich E, Hughes TF, Giesen DJ, Zhang T, Krauter CM, Winget P, Degenhardt M, Kyeremateng SO, Browning AR, Shelley JC.
    Mol Pharm; 2021 Nov 01; 18(11):3999-4014. PubMed ID: 34570503
    [Abstract] [Full Text] [Related]

  • 43. Amorphous solid dispersions containing residual crystallinity: Influence of seed properties and polymer adsorption on dissolution performance.
    Moseson DE, Parker AS, Beaudoin SP, Taylor LS.
    Eur J Pharm Sci; 2020 Apr 15; 146():105276. PubMed ID: 32092362
    [Abstract] [Full Text] [Related]

  • 44. Indomethacin-Kollidon VA64 Extrudates: A Mechanistic Study of pH-Dependent Controlled Release.
    Tres F, Treacher K, Booth J, Hughes LP, Wren SA, Aylott JW, Burley JC.
    Mol Pharm; 2016 Mar 07; 13(3):1166-75. PubMed ID: 26845251
    [Abstract] [Full Text] [Related]

  • 45. Impact of drug loading on the compaction properties of itraconazole-PVPVA amorphous solid dispersions.
    Zhang W, Sluga KK, Yost E, Phan J, Nagapudi K, Helen Hou H.
    Int J Pharm; 2022 Dec 15; 629():122366. PubMed ID: 36336201
    [Abstract] [Full Text] [Related]

  • 46. Effect of Formulation and Process Parameters on the Disproportionation of Indomethacin Sodium in Buffered Lyophilized Formulations.
    Koranne S, Thakral S, Suryanarayanan R.
    Pharm Res; 2018 Jan 05; 35(1):21. PubMed ID: 29305664
    [Abstract] [Full Text] [Related]

  • 47. The influence of hydrogen bonding between different crystallization tendency drugs and PVPVA on the stability of amorphous solid dispersions.
    Wu J, Mooter GVD.
    Int J Pharm; 2023 Nov 05; 646():123440. PubMed ID: 37742824
    [Abstract] [Full Text] [Related]

  • 48. Raman and thermal analysis of indomethacin/PVP solid dispersion enteric microparticles.
    Fini A, Cavallari C, Ospitali F.
    Eur J Pharm Biopharm; 2008 Sep 05; 70(1):409-20. PubMed ID: 18621516
    [Abstract] [Full Text] [Related]

  • 49. High drug loading nanosized amorphous solid dispersion (NASD) with enhanced in vitro solubility and permeability: Benchmarking conventional ASD.
    Andrews GP, Qian K, Jacobs E, Jones DS, Tian Y.
    Int J Pharm; 2023 Feb 05; 632():122551. PubMed ID: 36581107
    [Abstract] [Full Text] [Related]

  • 50. Dissolution-permeation of hot-melt extruded amorphous solid dispersion comprising an experimental grade of HPMCAS.
    Tanaka H, Miyano T, Ueda H.
    ADMET DMPK; 2023 Feb 05; 11(3):373-385. PubMed ID: 37829323
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Effect of preparation method on the surface properties and UV imaging of indomethacin solid dispersions.
    Asare-Addo K, Alshafiee M, Walton K, Ward A, Totea AM, Taheri S, Mawla N, Adebisi AO, Elawad S, Diza C, Timmins P, Conway BR.
    Eur J Pharm Biopharm; 2019 Apr 05; 137():148-163. PubMed ID: 30836178
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Impact of polymer type, ASD loading and polymer-drug ratio on ASD tablet disintegration and drug release.
    Zhang W, Noland R, Chin S, Petkovic M, Zuniga R, Santarra B, Conklin B, Hou HH, Nagapudi K, Gruenhagen JA, Yehl P, Chen T.
    Int J Pharm; 2021 Jan 05; 592():120087. PubMed ID: 33189812
    [Abstract] [Full Text] [Related]

  • 56. Initial Drug Dissolution from Amorphous Solid Dispersions Controlled by Polymer Dissolution and Drug-Polymer Interaction.
    Chen Y, Wang S, Wang S, Liu C, Su C, Hageman M, Hussain M, Haskell R, Stefanski K, Qian F.
    Pharm Res; 2016 Oct 05; 33(10):2445-58. PubMed ID: 27283830
    [Abstract] [Full Text] [Related]

  • 57. Effect of Solubility Improvement via Formation of an Amorphous Composite of Indomethacin and Sulindac on Membrane Permeability.
    Hatanaka Y, Uchiyama H, Furukawa S, Takase M, Yamanaka S, Kadota K, Tozuka Y.
    Chem Pharm Bull (Tokyo); 2023 Oct 05; 71(3):257-261. PubMed ID: 36858532
    [Abstract] [Full Text] [Related]

  • 58. Enhanced dissolution rate of nimodipine through β-lactoglobulin based formulation.
    Leng D, Bulduk B, Anlahr J, Müllers W, Löbmann K.
    Int J Pharm; 2023 Mar 25; 635():122693. PubMed ID: 36754186
    [Abstract] [Full Text] [Related]

  • 59. Moisture-Induced Amorphous Phase Separation of Amorphous Solid Dispersions: Molecular Mechanism, Microstructure, and Its Impact on Dissolution Performance.
    Chen H, Pui Y, Liu C, Chen Z, Su CC, Hageman M, Hussain M, Haskell R, Stefanski K, Foster K, Gudmundsson O, Qian F.
    J Pharm Sci; 2018 Jan 25; 107(1):317-326. PubMed ID: 29107047
    [Abstract] [Full Text] [Related]

  • 60. Release Mechanisms of Amorphous Solid Dispersions: Role of Drug-Polymer Phase Separation and Morphology.
    Yang R, Zhang GGZ, Zemlyanov DY, Purohit HS, Taylor LS.
    J Pharm Sci; 2023 Jan 25; 112(1):304-317. PubMed ID: 36306863
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.